NVCR
Novocure LtdNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$1.38B
P/E Ratio
—
EPS
$-1.22
Beta
0.82
52W High
$20.06
52W Low
$9.82
50-Day MA
$12.05
200-Day MA
$12.56
Dividend Yield
—
Profit Margin
-20.80%
Forward P/E
909.09
PEG Ratio
-0.47
About Novocure Ltd
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
Fundamentals
| Revenue (TTM) | $655.35M |
| Gross Profit (TTM) | $490.18M |
| EBITDA | $-135.16M |
| Operating Margin | -21.30% |
| Return on Equity | -38.90% |
| Return on Assets | -9.06% |
| Revenue/Share (TTM) | $5.88 |
| Book Value | $3.03 |
| Price-to-Book | 4.06 |
| Price-to-Sales (TTM) | 2.11 |
| EV/Revenue | 1.806 |
| EV/EBITDA | -6.92 |
| Quarterly Earnings Growth (YoY) | -6.00% |
| Quarterly Revenue Growth (YoY) | 8.10% |
| Shares Outstanding | $115.82M |
| Float | $94.97M |
| % Insiders | 9.97% |
| % Institutions | 81.35% |
Historical Volatility
HV 10-Day
50.76%
HV 20-Day
54.06%
HV 30-Day
56.50%
HV 60-Day
91.44%
HV Rank
39.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($25.07 target)
1
Strong Buy4
Buy2
HoldData last updated: 4/30/2026